François Goldwasser
#165,940
Most Influential Person Now
Researcher
François Goldwasser's AcademicInfluence.com Rankings
François Goldwasserbiology Degrees
Biology
#13446
World Rank
#16991
Historical Rank
Cell Biology
#746
World Rank
#762
Historical Rank
Molecular Biology
#2281
World Rank
#2315
Historical Rank
Neuroscience
#2331
World Rank
#2395
Historical Rank
Download Badge
Biology
François Goldwasser's Degrees
- PhD Biomedical Sciences Université Paris Cité
- Masters Biochemistry Université Paris Cité
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is François Goldwasser Influential?
(Suggest an Edit or Addition)François Goldwasser's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (2018) (3049)
- Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. (2011) (1053)
- Prevalence of malnutrition and current use of nutrition support in patients with cancer. (2014) (499)
- Controlling tumor growth by modulating endogenous production of reactive oxygen species. (2005) (475)
- Management of hypertension in angiogenesis inhibitor-treated patients. (2009) (324)
- Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel‐induced cancer cell death both in vitro and in vivo (2006) (306)
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. (2010) (261)
- Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma (2012) (260)
- Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. (1997) (209)
- Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients (2013) (205)
- TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma (2018) (195)
- Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. (2006) (182)
- Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. (1995) (178)
- Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. (2001) (167)
- Predicting High Grade Lesions of Sinusoidal Obstruction Syndrome Related to Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases: Correlation With Post-Hepatectomy Outcome (2010) (167)
- Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. (2004) (162)
- Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo (2012) (150)
- Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. (1996) (145)
- Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms (2006) (143)
- Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. (2012) (141)
- Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. (1999) (127)
- Emerging therapeutic options for breast cancer chemotherapy during pregnancy. (2008) (121)
- Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. (1999) (120)
- The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. (1995) (120)
- Use of platinum derivatives during pregnancy (2008) (118)
- Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. (2003) (114)
- Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. (2015) (114)
- Taxanes for breast cancer during pregnancy: a systematic review. (2010) (107)
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. (2009) (107)
- Posterior reversible encephalopathy syndrome induced by anti-VEGF agents (2011) (103)
- Sorafenib exposure decreases over time in patients with hepatocellular carcinoma (2012) (100)
- Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. (2002) (98)
- Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) (91)
- Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. (2012) (90)
- Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study (2012) (88)
- Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib (2011) (86)
- Drug interactions with solid tumour-targeted therapies. (2014) (85)
- Low influenza vaccination rate among patients receiving chemotherapy for cancer. (2008) (78)
- High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. (2008) (78)
- Body composition and sarcopenia: The next‐generation of personalized oncology and pharmacology? (2019) (78)
- Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. (2009) (77)
- Use of chemotherapy near the end of life: what factors matter? (2016) (75)
- Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. (2008) (73)
- A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. (2011) (73)
- Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. (2001) (70)
- An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. (2011) (69)
- Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients (2017) (68)
- Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses. (2001) (67)
- Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib (2011) (67)
- Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy. (2017) (67)
- Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment. (2014) (66)
- Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. (2007) (64)
- Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. (2012) (64)
- Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. (2014) (62)
- Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. (2006) (62)
- Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. (2005) (62)
- The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort (2019) (61)
- Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. (2009) (61)
- Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? (2007) (61)
- Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians—Results of the NutriCancer2012 Study (2017) (60)
- Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib (2018) (58)
- Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer (2012) (56)
- Hypertension as a surrogate marker for the activity of anti-VEGF agents. (2009) (55)
- Patient preference disability questionnaire in systemic sclerosis: a cross-sectional survey. (2008) (55)
- Impaired Tumor‐Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD‐1 Blockade (2018) (55)
- Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. (2000) (54)
- Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications (2016) (52)
- Toxicity of sorafenib: clinical and molecular aspects (2010) (52)
- Treatment of bevacizumab-induced hypertension by amlodipine (2012) (52)
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study (2020) (50)
- Protection against oxaliplatin acute neurosensory toxicity by venlafaxine (2003) (48)
- Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients (2011) (48)
- Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma (2016) (47)
- Nutrition chez le patient adulte atteint de cancer : textes courts (2012) (47)
- More on aprepitant for erlotinib-induced pruritus. (2011) (47)
- Sorafenib in advanced melanoma: a critical role for pharmacokinetics? (2012) (47)
- Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. (2017) (47)
- Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients (2015) (46)
- Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy (2017) (45)
- Saturable absorption of sorafenib in patients with solid tumors: a population model (2012) (43)
- Drug-induced effects on erlotinib metabolism. (2011) (42)
- The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. (2015) (42)
- Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. (2018) (41)
- Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib (2012) (40)
- Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. (2012) (38)
- Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine (2002) (38)
- Exacerbation of oxaliplatin neurosensory toxicity following surgery. (2002) (38)
- Liquid chromatography‐tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non‐small cell lung cancer patients (2018) (38)
- Chemotherapy for breast cancer during pregnancy: is epirubicin safe? (2008) (37)
- Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients (2012) (37)
- Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. (2006) (37)
- An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. (2013) (35)
- Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation (2015) (35)
- Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients (2011) (35)
- Clinical pharmacodynamic factors in docetaxel toxicity (2007) (35)
- NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer. (2018) (35)
- Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. (1996) (34)
- Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma (2011) (33)
- Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. (2012) (32)
- Pancreatic atrophy--a new late toxic effect of sorafenib. (2013) (31)
- Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. (1995) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients (2004) (30)
- Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib (2015) (30)
- Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy (2016) (29)
- Resting energy expenditure in the risk assessment of anticancer treatments. (2017) (29)
- Development and validation of an ELISA method for the quantification of nivolumab in plasma from non‐small‐cell lung cancer patients (2017) (29)
- Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence (2020) (29)
- Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. (2012) (29)
- Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. (1999) (28)
- Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. (2012) (27)
- Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. (2008) (25)
- Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients (2017) (25)
- Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation (2019) (25)
- The impact of body composition parameters on severe toxicity of nivolumab. (2019) (25)
- Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells (2018) (25)
- Large artery stiffness and hypertension after antiangiogenic drugs: influence on cancer progression (2015) (25)
- Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assessement of low lean body mass in cancer patients: Comparison to L3-computed tomography scan. (2020) (24)
- VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption (2011) (24)
- Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients? (2019) (23)
- Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. (2011) (23)
- Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study (2018) (23)
- Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study (2011) (23)
- Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. (1999) (23)
- Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities (2005) (23)
- Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib. (2010) (23)
- Combination of Topotecan and Oxaliplatin in Inoperable Hepatocellular Cancer Patients (2002) (23)
- Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi‐cohort analysis (2021) (22)
- Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. (1999) (22)
- Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma (2010) (22)
- Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy. (2012) (21)
- Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form (2011) (21)
- Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients (2012) (21)
- Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers (2018) (20)
- Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies (2013) (20)
- Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis (2012) (20)
- Respect des volontés en fin de vie : étude de faisabilité d’une information sur la personne de confiance et les directives anticipées (2015) (20)
- Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma. (2008) (20)
- Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review (2016) (19)
- Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old (2017) (19)
- A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors (2007) (18)
- Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer (2014) (18)
- Advances in pancreatic neuroendocrine tumor treatment. (2011) (18)
- Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry‐based study (2018) (18)
- Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey. (2018) (18)
- Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity (2017) (17)
- Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity? (2014) (17)
- Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcoma. (2012) (17)
- Ectopic pregnancy in a breast cancer patient receiving trastuzumab. (2008) (17)
- Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients (2014) (17)
- Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer. (2012) (17)
- Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. (1996) (16)
- Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status (2011) (16)
- Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient. (1995) (16)
- The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab (2014) (16)
- Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study (2016) (16)
- Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib (2016) (16)
- A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors (2014) (16)
- Objective response to sorafenib in advanced clear-cell sarcoma. (2012) (15)
- Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 Study. (2018) (15)
- Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. (2012) (15)
- Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France (2017) (14)
- Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial (2019) (14)
- Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication (2017) (14)
- Ambulatory administration of 5-day infusion ifosfamide + mesna: a pilot study in sarcoma patients (2010) (14)
- Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options (2018) (14)
- Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2 (2012) (14)
- Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely (2020) (14)
- Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. (2020) (14)
- Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS) (2014) (13)
- First referral to an integrated onco-palliative care program: a retrospective analysis of its timing (2017) (13)
- Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient. (2009) (13)
- A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. (2015) (13)
- Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients (2017) (13)
- A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors (2006) (13)
- Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease. (2011) (13)
- Prise d’antioxydants et d’autres thérapies complémentaires par les patients sous chimiothérapie antitumorale : étude prospective (2011) (13)
- Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker. (2016) (13)
- Validation of the Cochin Risk Index Score (CRIS) for life expectancy prediction in terminally ill cancer patients (2012) (12)
- Redifferentiating effect of larotrectinib in NTRK-rearranged advanced radioactive-iodine refractory thyroid cancer. (2022) (12)
- A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. (2017) (12)
- Chronotherapy of Colorectal Liver Metastases (2002) (12)
- [Respecting patient's end of life wishes: feasibility study of an information on surrogate and advance directives]. (2015) (12)
- Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis (2016) (12)
- Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. (2020) (12)
- Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer (2017) (12)
- O017 Effets des cancers sur l’état nutritionnel et la prise alimentaire : la perception des malades (2007) (12)
- Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours (2019) (12)
- Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. (2000) (12)
- Bystander effect of vinorelbine alters antitumor immune response (2011) (12)
- A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. (2012) (12)
- Pericardial effusion under nivolumab: case-reports and review of the literature (2019) (11)
- Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. (2019) (11)
- Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient. (2000) (11)
- Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. (2017) (11)
- Nutrition chez le patient adulte atteint de cancer : introduction (2012) (11)
- Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. (2002) (11)
- Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience (2009) (11)
- Cellular pharmacology of azatoxins (topoisomerase‐II and tubulin inhibitors) in P‐glycoprotein‐positive and ‐negative cell lines (1995) (10)
- Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case–control study (2012) (10)
- Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients. (2011) (10)
- Reactivation of tuberculosis during temsirolimus therapy (2011) (10)
- Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. (2012) (10)
- Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma (2020) (10)
- Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents (2011) (10)
- Nivolumab combined with ruxolitinib: antagonism or synergy? (2018) (10)
- Public health oncology : a framework for progress in low-and middle-income countries † (2012) (10)
- La décision médicale en cas de cancer incurable (2010) (10)
- Chronotherapy of colorectal cancer metastases. (2001) (10)
- Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients (2012) (9)
- Treatment of Advanced Renal-Cell Carcinoma. (2016) (9)
- Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index (2021) (9)
- Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments (2020) (9)
- Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. (2020) (9)
- Resting energy metabolism and anticancer treatments (2018) (9)
- Efficacy of venlafaxine for the prevention and relief of acute neurotoxicity of oxaliplatin: Results of EFFOX, a randomized, double-blinded, placebo-controlled prospective study. (2009) (9)
- Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer. (2013) (9)
- Sarcopenia and toxicity of the anti-PD1 inhibitors in real-life lung cancer patients: Results from the French Nationwide SCAN study. (2018) (8)
- Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. (2010) (8)
- A PK/PD study of Delta‐4 abiraterone metabolite in metastatic castration‐resistant prostate cancer patients (2018) (8)
- Cisplatin as a cornerstone of modern chemotherapy. (2009) (8)
- Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients. (2016) (8)
- Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies (2014) (8)
- The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases. (2002) (8)
- Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better. (2014) (8)
- Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics (2015) (8)
- The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of α-fetoprotein or β-human chorionic gonadotrophin: report of two cases (2002) (8)
- Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. (2016) (8)
- Sorafenib for patients with differentiated thyroid cancer (2015) (8)
- Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters (2015) (7)
- Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. (2015) (7)
- Unexpected diagnosis for an adrenal tumor: synovial sarcoma. (2010) (7)
- Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study (2021) (7)
- The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas (2019) (7)
- Sorafenib for patients with differentiated thyroid cancer (2015) (7)
- La réunion de concertation pluridisciplinaire onco-palliative : objectifs et préconisations pratiques (2018) (6)
- A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma (2016) (6)
- 704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC) (2007) (6)
- The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study) (2021) (6)
- 3051 POSTER Effect of Denosumab Treatment on Prevention of Hypercalcemia of Malignancy in Cancer Patients With Metastatic Bone Disease (2011) (6)
- [Adamantinoma of the proximal end of the tibia. A case]. (1994) (6)
- Cancer during pregnancy: Factors associated with termination of pregnancy and perinatal outcomes. (2021) (6)
- Multicenter Randomized Phase 2 Trial of Gemcitabine – Platinum with or without Trastuzumab (T) in Advanced / Metastatic Urothelial Carcinoma (A/MUC) with HER2 Overexpression (2012) (6)
- Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results (2004) (6)
- Inhibiteurs de tyrosine kinase ciblant l’angiogenèse et sujets âgés : tolérance, évaluation pré-thérapeutique et gestion des effets indésirables (2016) (6)
- Toxicité rénale du méthotrexate à haute dose (2018) (6)
- [Renal toxicity of high-dose methotrexate]. (2018) (6)
- Decision making process in oncology practice: is the information available and what should it consist of? (2005) (6)
- Is sarcopenia a missed factor in the management of patients with metastatic breast cancer? (2021) (6)
- [Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study]. (2011) (6)
- Tolérance rénovasculaire du bévacizumab dans le cancer du sein. Valeur pronostique de l’hypertension et de la protéinurie (2015) (6)
- Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer (2007) (5)
- Sorafenib in thyroid cancer patients: learning from toxicity. (2014) (5)
- Les essais thérapeutiques de phase I en cancérologie : enjeux éthiques (2004) (5)
- Métastases oculaires. Revue de la littérature à propos de quatre observations (1994) (5)
- Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa (2021) (5)
- Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer (2020) (5)
- Predictive and prognostic value of systemic inflammatory response biomarkers in patients receiving nivolumab for metastatic non-small cell lung cancer (NSCLC). (2017) (5)
- Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. (2001) (5)
- First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas. (2012) (5)
- Nutritional Status Is Superior to the ECOG Performance Status in Predicting the Dose-Intensity of the GEMOX Chemotherapy Regimen in Patients with Advanced Cancer (2013) (5)
- Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study (2021) (5)
- Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients. (2014) (5)
- Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma? (2014) (5)
- Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer (2019) (4)
- Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. (2020) (4)
- Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC) (2008) (4)
- Abstract P3-15-06: Results of the MARS study on the management of antiangiogenics’ renovascular safety in breast cancer (2013) (4)
- Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms. (2007) (4)
- BRCA2 Loss‐of‐Function and High Sensitivity to Cisplatin‐Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine (2018) (4)
- Sarcopenia associated with a body mass index (BMI) > 25 kg/m2 predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients (2016) (4)
- Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer (2022) (4)
- Paclitaxel (Taxol)-associated junctional tachycardia. (1997) (4)
- Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma. (2014) (4)
- Métastases osseuses : prise en charge multidisciplinaire, approche diagnostique et thérapeutique (2012) (4)
- Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab (2019) (4)
- Biomarqueurs prédictifs de l’immunothérapie anti-PD1/PD-L1 dans le cancer broncho-pulmonaire non à petites cellules (2018) (4)
- Les cancers en phase chronique : Nouveaux défis, nouvelles pluridisciplinarités. (2017) (4)
- Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. (1998) (4)
- Characterizing the risk of drug-drug interactions in sarcoma treated patients: Role of pharmacist integration. (2018) (4)
- Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study (2018) (4)
- A painful cranial bulge (2011) (4)
- Evidence of a reduced DNA topoisomerase II mRNA expression after ionizing radiation. (1999) (3)
- CYP3A4/5 and pharmacogenetics in patients with sarcoma. (2007) (3)
- [Multidisciplinary oncopalliative meeting: Aims and pratical recommendations]. (2018) (3)
- Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study. (2021) (3)
- Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). (2007) (3)
- [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria]. (2015) (3)
- [Use of sorafenib in patients with hepatocellular or renal carcinoma]. (2010) (3)
- Evaluation of the interindividual variability in plasma nivolumab level in non-small-lung cancer outpatients: preliminary results (2016) (3)
- Abstract 4546: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort (2018) (3)
- Soluble VEGFR‐1: A new biomarker of sorafenib‐related hypertension (2015) (3)
- Topoisomerase II Inhibitors: Current Use and Prospects (2012) (3)
- SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils. (2022) (3)
- Les cancers de l’ovaire associés à l’endométriose : physiopathologie et conséquences sur la pratique clinique (2013) (3)
- Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid (2016) (3)
- Management of Cancer Cachexia: ASCO Guideline-Time to Address the Elephant in the Room. (2020) (3)
- Proposal of a new population pharmacokinetics (PK) model of sorafenib and rationale for a three-daily schedule. (2010) (3)
- [Endometriosis-associated ovarian cancers: pathogenesis and consequences on daily practice]. (2013) (3)
- Clinical Approach in Soft Tissue Tumors (2011) (3)
- Targeting angiogenesis in chronic liver diseases with portal hypertension: anti–placenta growth factor inhibitor or multikinase inhibitor sorafenib? (2011) (3)
- Objective response to sorafenib in advanced clear-cell sarcoma. (2012) (3)
- Angiotensin System Inhibitors in Renal Cell Carcinoma—Letter (2016) (3)
- Cervical extravasation of bevacizumab. (2013) (3)
- Prevalence of malnutrition in lung cancer patients: a one-day survey: P1-257 (2007) (3)
- Traitement du cancer colorectal métastatique : une illustration de l’évolution des concepts fondateurs de la cancérologie (2012) (3)
- [Management of metastatic castration-resistant prostate cancer following docetaxel]. (2012) (3)
- Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). (2021) (3)
- Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. (2016) (3)
- [Clinical use of oxaliplatin in solid tumors]. (2001) (3)
- Bon usage du sorafénib chez les patients pris en charge pour un carcinome hépatocellulaire ou un cancer du rein (2010) (3)
- L’organisation française en réseau de soins pour la prise en charge des sarcomes (2016) (3)
- [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. (2016) (2)
- Incidence of chemotherapy-induced nausea and vomiting in 2008. (2009) (2)
- Association between High Antitumor Activity of Oxaliplatin and Cyclophosphamide and Constitutional GSTM1 Homozygous Deletion in an Advanced Ovarian Cancer Patient (2014) (2)
- Diagnostic Performance of the 4-item Geriatric Depression Scale for Depression Screening in Older Patients with Cancer: The ELCAPA Cohort Study. (2021) (2)
- Failure in DNA Elongation Predicts Sensitivity to Camptothecin in the Colon Cell Lines of the NCI Anticancer Drug Screen (1996) (2)
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib—Letter (2015) (2)
- [Crossed perceptions about malnutrition in patients and their doctors in oncology]. (2017) (2)
- Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma (2017) (2)
- Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma (2017) (2)
- Pharmacokinetic/pharmacodynamic relationship of enzalutamide and its active metabolite N-desmethyl enzalutamide in metastatic castration-resistant prostate cancer patients. (2018) (2)
- [Treatment of metastatic colorectal cancer: an illustration of the changes in the cancer paradigms]. (2012) (2)
- RE: Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. (2019) (2)
- Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer (2022) (2)
- Pancreatic atrophy from sorafenib. (2014) (2)
- Correlation of sorafenib plasma concentrations and clinical toxicity: A prospective population pharmacodynamic and pharmacokinetic study. (2009) (2)
- [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]. (2018) (2)
- An original administration of ifosfamide given once every other week: a clinical and pharmacological study (2008) (2)
- [IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?] (2018) (2)
- Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options (2023) (2)
- Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma. (2010) (2)
- [New challenges in medical oncology. From medical oncology to oncological medicine]. (2003) (2)
- A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). (2012) (2)
- High prevalence but low recognition of sarcopenia in metastatic cancer patients: Results of the scan study (2018) (2)
- Oxaliplatin in inoperable or metastatic bladder cancer. (2006) (2)
- Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors. (2011) (2)
- Effect of nivolumab therapy on pulmonary artery. (2017) (2)
- Relationship between performance status and malnutrition in non-selected cancer patients: A nation-wide one-day survey (2007) (2)
- A pharmacogenomic scoring system predicting median time to progression (mTTP) on sunitinib (SUN) as first-line treatment in patients (pts) with metastatic renal cell carcinoma (mRCC). (2012) (2)
- Decision-making in incurable cancers : A retrospective analysis of 150 patients entered into the CTRL algorithm of Cochin. (2004) (2)
- Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management (2021) (2)
- Enjeux et écueils des thérapies ciblées orales en pratique clinique quotidienne : 5e journée de pharmacologie des anti-tumoraux (2018) (2)
- Dénutrition hospitalière – Clans – UTNO50 Évolution de la prévalence de la dénutrition et de sa prise en charge chez des malades atteints de cancer en France** (2013) (2)
- Recommandations professionnelles Nutrition chez le patient adulte atteint de cancer : textes courts SFNEP oncology nutrition guidelines : Summary of statements (2012) (2)
- Prise en charge des cancers de prostate résistants à la castration métastatiques après échec du docétaxel (2012) (2)
- [Metastatic eye neoplasms. Review of the literature apropos of 4 cases]. (1994) (1)
- P180 Regards des médecins en charge des malades atteints de cancer sur la dénutrition et sa prise en charge (2013) (1)
- [Clinical pharmacology and immunotherapy, 4th edition of the congress of pharmacology of anticancer drugs]. (2017) (1)
- [Chemotherapy in unfit bladder cancer patients]. (2010) (1)
- Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity? (2014) (1)
- La cancérologie clinique: entre exigence d’efficience et devoir d’humanisme (2008) (1)
- [Multidisciplinary and systematic preoperatory-assessment in geriatric urologic oncology surgery: Feasibility and results]. (2019) (1)
- Burden of inpatient care and treatments in terminally-ill cancer patients: results from a population-based, retrospective study from administrative data in France. (2015) (1)
- Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers (2022) (1)
- 1578 Resting energy expenditure (REE) for risk assessment of anticancer treatments: A prospective study in 277 cancer patients (2015) (1)
- [Biotherapies in metastatic colorectal cancers in 2014]. (2014) (1)
- Short report Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports (2005) (1)
- Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. (2021) (1)
- [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs]. (2018) (1)
- Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patients. (2022) (1)
- Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer (2017) (1)
- Intérêt du rapport créatinine/cystatine C et de l’impédancemétrie bioélectrique (BIA) dans l’évaluation de la composition corporelle chez le patient atteint de cancer (2019) (1)
- Représentations croisées sur l’alimentation et la dénutrition chez les patients atteints de cancer : résultats de l’étude NutriCancer2012 (2017) (1)
- Chimiothérapie des patients atteints de cancer de vessie et unfit (2010) (1)
- Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy. (2016) (1)
- [Red blood transfusion in palliative care situation]. (2016) (1)
- Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients (2022) (1)
- Recommandations pour la pratique clinique : Standards, Options : Recommandations 2008 pour la prise en charge des patientes atteintes de tumeurs épithéliales malignes de l’ovaire. Traitement médical de première ligne (rapport abrégé) (2008) (1)
- Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma. (2022) (1)
- Goals and aggressiveness of care in metastatic lung cancer. (2016) (1)
- Thérapeutiques ciblées anti-ErbB et tumeurs urothéliales. (2005) (1)
- CT-defined Sarcopenia Prevalence in Patients With Metastatic Cancer: A Cross-sectional Multicenter French Study (the SCAN Study) (2021) (1)
- Vinorelbine plus oxaliplatin in unfit patients (pts) with stage IV non-small cell lung cancer (NSCLC) (2008) (1)
- Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems (2019) (1)
- la loi Léonetti (2010) (1)
- Predictive factors associated with pemetrexed acute toxicity (2023) (1)
- Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. (2022) (1)
- Irofulven (IROF) combined with oxaliplatin (OXA) in advanced hepatocellular carcinoma (HCC) patients (pts): Phase I study (preliminary results). (2006) (1)
- Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer. (2016) (1)
- Slow natural history predicts higher response rate to nivolumab and pembrolizumab in advanced melanoma patients (2016) (1)
- 1396P Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM cohort: The ELY study (2020) (1)
- Is thrombotic microangiopathy associated with antitumoral activity? (2006) (1)
- IHC, FISH, CISH, NGS dans les cancers bronchiques non à petites cellules : quelles évolutions dans l’ère des biomarqueurs ? (2018) (1)
- Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d’Etude des Tumeurs Uro-Génitales). (2016) (1)
- Early TKI-pharmokinetics and circulating tumor DNA (ctDNA) to predict outcome in patients with EGFR-mutated non-small cell lung cancer (NSCLC). (2017) (1)
- Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report (2023) (1)
- [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs]. (2018) (1)
- Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients. (2015) (1)
- Nutrition and cancer 1SUN-P098: Hypermetabolism in the Elderly Cancer Patient: A Pilot Study (2017) (1)
- Relationship Between Intestinal Function and Exposure to Sorafenib and Sunitinib in Cancer Patients (2012) (1)
- Prospective study of predictive factors of docetaxel (DCX)-induced febrile neutropenia (FN): Relevance of in vivo cytochrome 3A (CYP3A) phenotyping (2005) (1)
- Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma (2018) (1)
- Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key. (2018) (1)
- Directives anticipées en dermato-oncologie : situation actuelle et perspectives (2015) (1)
- 1444PSARCOPENIA AND ACUTE SEVERE TOXICITY IN SARCOMA PATIENTS TREATED WITH DOXORUBICIN-BASED CHEMOTHERAPY. (2014) (1)
- Arterial stiffness to predict hypertensive response to antiangiogenic drugs. (2013) (1)
- L’information sur le pronostic : quel sens pour les patients ? (2015) (1)
- Estimation of glomerular filtration rate in patients with abnormal body composition and relation with carboplatin toxicity (2016) (1)
- Chemotherapy in non-selected elderly patients: Factors influencing dose-intensity and toxicity (2007) (1)
- Differential modulation of oxidative stress in normal and cancer cells by mangafodipir improves the therapeutic index of anticancer drugs (2005) (1)
- Creatinine to cystatin c ratio (sarcopenia index) is a predictor of mortality in cancer patients (2020) (1)
- A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma (2022) (1)
- Tolérance des patients de plus de 85 ans traités par anti-PD1 dans le mélanome (2016) (1)
- Nutrition en cancérologie : un axe thérapeutique central (2014) (1)
- Concomitant sorting of circulating tumor cell subpopulations in cancer patients’ blood samples through the multiplexed immunosensor combination design (2018) (1)
- Les biothérapies des cancers colorectaux métastatiques en 2014 (2014) (1)
- Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study. (2014) (1)
- Complication-related removal of totally implantable venous access port systems: Do not forget the skin scar in survivors! (2017) (1)
- How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study. (2013) (1)
- Evidence for enhanced toxicity to CPT-11 in patients with Gilbert's syndrome: Two case reprots (1997) (1)
- Les poisons des topo-isomérases I (2007) (1)
- Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature (2019) (1)
- A multicentric phase II trial of gemcitabine (Gem), oxaliplatin (Oxa) and vinorelbine (VNB) in untreated stage IIIB and IV non-small cell lung cancer (NSCLC) patients (pts): Preliminary results of GON triplet regimen. (2006) (1)
- [Advance directives in dermato-oncology: The current situation and future prospects]. (2016) (1)
- P181 Patients, proches et médecins n’ont pas la même vision de la dénutrition en cancérologie. Résultats de l’étude NUTRICANCER 2012 ** (2013) (1)
- Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab (2022) (1)
- Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma. (2018) (1)
- Management of antiangiogenics’ renovascular safety in breast cancer subgroup and intermediate results of the MARS study. (2012) (1)
- Évolution de la fonction rénale sous-antiangiogéniques. Résultats de l’étude MARS (2013) (1)
- High plasma concentrations of acyl‐coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP (2022) (1)
- Relationship between glutathione-S-transferase P1 Ile105Val polymorphism and docetaxel neurosensory toxicity (2007) (1)
- Phase II trial of every 2 weeks dosing of irofulven (IROF) in patients (pts) with unresectable hepatocellular carcinoma (HCC): preliminary results. (2004) (1)
- Réponse durable avec une association FOLFIRI/bévacizumab dans un cas de tumeur de l'ouraque métastatique (2007) (1)
- Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA? (2022) (1)
- Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab. (2022) (1)
- 2747 A real life experience of bevacizumab in elderly women with advanced ovarian carcinoma (2015) (1)
- Reply to S.M. Sorscher et al (2011) (1)
- Hyper-alkalinization instead of hyper-hydration for the prevention of high-dose methotrexate (HDMTX) induced nephrotoxicity in osteosarcoma patients (2005) (1)
- Concomitant administration of high-dose methotrexate (HDMTX) and ifosfamide in osteosarcoma patients: A clinico-pharmacological study (2005) (1)
- MON-P116: PI3KINASE-AKT-Mtor Pathway and Glutamine Metabolism in Ovarian Cancer (2017) (0)
- Abstract 3721: Relationship between insulin resistance and chemosensitivity of high grade bone sarcoma (2020) (0)
- Biomarqueurs prédictifs et inhibiteurs des points de contrôle immunitaires au cours des cancers bonchopulmonaires non à petites cellules (2019) (0)
- Ifosfamide given once every other week: A clinical and pharmacological study (2007) (0)
- Abstract 1693: Prediction of the efficacy of nivolumab using resting energy expenditure in metastatic non-small cell lung cancer (mNSCLC) patients (2018) (0)
- H2O2 accumulation is a crucial step for the cytotoxicity of Paclitaxel (2004) (0)
- Reversible tumor metastases growth acceleration following bevacizumab interruption and surgical resection of metastases (2007) (0)
- Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors. (2023) (0)
- OR43: Creatinine to Cystatin C Ratio and BIA for the Assessement of Low Lean Body Mass in Cancer Patient: Comparaison to L3 CT-Scan (2019) (0)
- Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue. (2016) (0)
- Feasibility of a multi-disciplinary rehabilitation program for post treatment cancer patients: A pilot study. (2015) (0)
- Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept. (2015) (0)
- 1549P Pazopanib exposure in advanced soft tissue and bone sarcoma: A pharmacokinetic/pharmacodynamic analysis (2021) (0)
- 1304 Experience of a monocentric center: Soft-tissue sarcoma in elderly (2015) (0)
- 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota (2022) (0)
- 1549PHYPERTENSION, PROTEINURIA AND OVERALL SURVIVAL IN ELDERLY CANCER PATIENTS TREATED WITH BEVACIZUMAB. (2014) (0)
- 1048P Should I stay or should I go: Optimal duration for antiPD(L)1 therapy (2020) (0)
- 3056 Risk factors for severe anaemia: a prospective, multicentric, observational survey of 645 patients treated with first-line chemotherapy (INDEX study) (2009) (0)
- Iconography : Les cancers de l’ovaire associés à l’endométriose : physiopathologie et conséquences sur la pratique clinique (2013) (0)
- L’index de sarcopénie est un marqueur de survie globale chez les patients atteints de cancer (2021) (0)
- Chapitre 23. Soins palliatifs en cancérologie (2020) (0)
- O041 - Influence de 3 mois de nutrition entérale à domicile (NEAD) sur la qualité de vie (QdV) des patients : une étude observationnelle prospective et multicentrique (2010) (0)
- Optimisation thérapeutique par la gestion des toxicités : expérience du Centre d’Étude et de Recours sur les Inhibiteurs de l’Angiogenèse (CERIA) (2013) (0)
- Camptothecin in Human Colon Carcinoma Cells Arrest and the Cytotoxicity of 2 Correlations between S and G Updated (2006) (0)
- A multidisciplinary team dedicated to the management of patients treated with PD1 inhibitors: The Cochin hospital experience. (2016) (0)
- Chapitre 35 – Approche psychologique avec le patient atteint de cancer: Quelques repères (2016) (0)
- Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult patients with cancer with advanced solid tumors. (2011) (0)
- Risque vasculaire des médicaments anti-angiogéniques et athérome (2010) (0)
- Hypermétabolisme chez le patient âgé atteint de cancer-une étude pilote (2017) (0)
- Biothérapies et sujets âgés (2008) (0)
- Iconographies supplémentaires de l'article : Métastases osseuses : prise en charge multidisciplinaire, approche diagnostique et thérapeutique (2012) (0)
- Prevalence of malnutrition in PS 0-1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients. (2015) (0)
- Hypermétabolisme, cachexie et toxicité des traitements anti-tumoraux : étude prospective chez 277 patients atteints de cancer (2016) (0)
- La sarcopénie est sous-diagnostiquée chez les patients atteints de cancer métastatique : résultats de l’étude SCAN (2019) (0)
- Étude de l’insulinorésistance et du syndrome métabolique dans une cohorte de patients atteints de cancer (2013) (0)
- Determinants cellulaires de la cytotoxicite de la camptothecine (1996) (0)
- Insuffisance rénale aiguë après méthotrexate haute-dose : impact de la glucarpidase (2017) (0)
- Les métastases osseuses au cours des cancers broncho-pulmonaires (2013) (0)
- Concentration sérique du vémurafénib (2012) (0)
- Données d’efficacité et de toxicité des immunothérapies anti cancéreuses chez le sujet âgé – 5e journée de pharmacologie des anti-tumoraux (2018) (0)
- Les auteurs (2020) (0)
- Le traitement médical du cancer colorectal métastatique : Une illustration de la validité des concepts fondateurs de la chimiothérapie (2002) (0)
- O42 Facteurs associés à l’amélioration de la qualité de vie chez les patients atteints de cancer et recevant 3 mois de nutrition entérale à domicile (2011) (0)
- Carcinogenèse et tabagisme. A propos d'un cas avec atteinte tumorale pluri-focale des muqueuses malpighiennes (1993) (0)
- Regards croisés sur la dénutrition en cancérologie ORL. Résultats à partir de l’étude NUTRICANCER 2012 (2013) (0)
- Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study (2022) (0)
- Interaction médicamenteuse entre mitotane et etoposide dans le traitement des corticosurrénalomes (2018) (0)
- Processus décisionnel chez le patient atteint de cancer en défaillance vitale (2010) (0)
- L’alpha-cétoglutarate, précurseur et métabolite de la glutamine, supporte-t-il la viabilité et la migration des cellules tumorales ovariennes glutamino-dépendantes ? (2020) (0)
- Actualités et perspectives concernant l’immunothérapie au cours des CBNPC (2018) (0)
- Topotécan (Hycamtin®) : Données actuelles et perspectives dans le cancer de l'ovaire (1997) (0)
- Impact of sarcopenia (Sp) on early dose-limiting toxicity (DLT) and acute vascular toxicity in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib (SUT). (2011) (0)
- Treating breast cancer with trabectedin: a new arsenal (2014) (0)
- Croyances et idées reçues sur l’alimentation au cours des traitements des cancers (2019) (0)
- [Integrated podiatrist care for prostate cancer patients treated with docetaxel: Feasibility and results]. (2018) (0)
- Lichen plan chez des patients traités par anti-PD1 : 6 cas (2018) (0)
- Prolifération de trois lignées humaines de carcinome ovarien présentant des profils métaboliques différents vis-à-vis du glucose et de la glutamine (2016) (0)
- La sarcopénie associée à un IMC > 25 kg/m2 est prédictive de toxicité sévère précoce sous anti-PD1 chez les patients atteints de mélanome (2016) (0)
- O50 Évolution de la prévalence de la dénutrition et de sa prise en charge chez des malades atteints de cancer en France (2013) (0)
- Une histoire naturelle lente est associée à un meilleur taux de réponse aux anti-PD1 dans le mélanome (2016) (0)
- Cancers bronchiques non à petites cellules (CBNPC) résécables et immunothérapie : état des lieux et perspectives (2020) (0)
- Soins palliatifs en cancérologie (2014) (0)
- Traitement du cancer colorectal : des révolutions en marche (2012) (0)
- Le nivolumab augmente la pression artérielle pulmonaire chez les patients traités pour carcinome pulmonaire non à petites cellules (2021) (0)
- L'utilisation clinique de l'oxaliplatine dans les tumeurs solides (2001) (0)
- Prise en charge des ostéosarcomes de l’adulte (2008) (0)
- Traitement systemique des metastases osseuses : Les métastases osseuses vertébrales (2002) (0)
- Nutrition and Cancer: An Epidemiological Study in France. Focus in Hematology. (2006) (0)
- Prevention of high-dose methotrexate acute toxicity using a rescue protocol combining hyper-alkalinization followed by continuous infusion of leucovorin in osteosarcoma patients (2008) (0)
- Évaluation pluridisciplinaire préopératoire systématique en chirurgie cancérologique urologique gériatrique : faisabilité et résultats (2019) (0)
- Critères de choix thérapeutique en oncologie : définition et intérêt d’un nouvel index d’efficacité relative des agents antitumoraux (In-RATE) (2008) (0)
- Les cancers en phase chronique (2017) (0)
- Validation of a scoring system to improve life expectancy prediction in advanced cancer patients. (2016) (0)
- Microangiopathie thrombotique secondaire au sunitinib révélée par des crises convulsives (2009) (0)
- Intérêt des outils cliniques pour prédire la sarcopénie chez les patients atteints de cancer métastatique : résultats de l’étude SCAN (2019) (0)
- Impact des recommandations HAS 2019 concernant le diagnostic de la dénutrition sur sa prévalence en cancérologie (2021) (0)
- Sarcoïdose sous inhibiteur de BRAF : une activation paradoxale auto-immune ☆ (2014) (0)
- Soins podologiques intégrés chez les patients atteints de cancer de prostate traités par docétaxel : faisabilité et résultats (2018) (0)
- Abstract 4609: High-grade TP53-mutated endometrial carcinomas have decreased NRF2 antioxidant activity (2018) (0)
- Approche psychologique avec le patient atteint de cancer. Quelques repères (2020) (0)
- Acknowledgement to Referees for Dermatology 2015 (2015) (0)
- Low skeletal muscle mass is clinically underestimated in advanced metastatic prostate cancer: the cross-sectional SCAN study (2022) (0)
- 0247: Changes in blood pressure and arterial mechanical properties after antiangiogenic drugs: association with cancer progression and mortality (2014) (0)
- Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib? (2015) (0)
- Ecteinascidin-74 3: A M arine-Derived C ompound i n Advanced, P retreated S arcoma P atients—Prelimi nary Evidence o f A ctivity (2001) (0)
- Evaluation of baseline asymptomatic dysimmunity prevalence in cancer patients receiving monoclonal anti-PD1 antibodies. (2016) (0)
- Hepatic and renal tolerance of immune checkpoint inhibitors for cancer treatment: A retrospective monocentric cohort study (2018) (0)
- P97 Bevacizumab-induced hypertension in ≥70 years-old patients with metastatic solid tumors (2009) (0)
- PP082-SUN PATIENTS, RELATIVES AND DOCTORS HAVE DIFFERENT POINT OF VIEW ON MALNUTRITION IN ONCOLOGY. A FRENCH ONE-DAY SURVEY NUTRICANCER 2012 (2013) (0)
- 1319 A prevalence study of drug-drug interactions in metastatic prostate cancer patients receiving abiraterone (2015) (0)
- Transfusion de globules rouges en situation oncologique palliative (2016) (0)
- Experimentation of ‘Link for Health’, a new Telehealth application in Cochin Hospital, France (2017) (0)
- Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial. (2017) (0)
- Characteristics Of Hypometabolic Cancer Patients (2023) (0)
- Reply to Bone morphogenetic proteins and zoledronic acid. (2009) (0)
- 3064 POSTER Malnutrition: a Therapeutic Target in Oncology – Results of a Multicentre Observational Study in 391 Cancer Patients (2011) (0)
- Does visceral fat area (VFA) have predictive value for hypertension (HTN) and progression-free survival (PFS) in patients (pts) with stage IV NSCLC receiving bevacizumab (Beva)? (2011) (0)
- End-of-life discussions with noncurable lung cancer patients: A patients' and oncologists' qualitative study. (2014) (0)
- Abstract 4955: Impact of PD-1, PD-L1 and EBI3 on prognosis in a cohort of localized high grade undifferentiated pleomorphic sarcoma patients (2019) (0)
- Abstract 573: Mutations found by targeted next generation sequencing is associated with intra-tumor immune profile and may predict response to anti-PD1 therapy in lung adenocarcinoma (2019) (0)
- Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort. (2022) (0)
- Hypertension, proteinuria, and overall survival in elderly cancer patients treated with bevacizumab. (2014) (0)
- Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors. (2015) (0)
- This information is current as Model of Colon Cancer Mediated by Oxidative Stress in a Murine through Regulatory T Cell Depletion Arsenic Trioxide Exerts Antitumor Activity (2012) (0)
- Relationship between large arteries changes, antiangiogenic drugs pharmacokinetics and cancer response (2014) (0)
- 8003 ORAL Experience With Bevacizumab in the Management of Relapsed Ovarian Cancer – a Retrospective Observational Study in Five French Hospitals (2011) (0)
- La citrulline comme marqueur de masse active entérocytaire : un facteur pronostique de la réponse à l’immunothérapie (2021) (0)
- TCRM_A_263832 683..698 (2022) (0)
- SUN-PP123: The Role of Hypermetabolism in Cancer Cachexia: A Prospective Study in 310 Cancer Patients Prior Chemotherapy Initiation (2015) (0)
- Abstract 4107: Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab efficacy in advanced non-small cell lung cancer (2019) (0)
- Predicting acute early limiting toxicity from anticancer treatment in older patients: impact of basal energy metabolism (2021) (0)
- Incidence of Organizing Pneumonia Induced by Oxaliplatin Chemotherapy for Digestive Cancer (2015) (0)
- O20: Regards croisés divergents des patients de plus de 70 ans et médecins sur la dénutrition en cancérologie : Résultats de l’étude NUTRICANCER 2012 (2014) (0)
- PP106-SUN RELATIONSHIP BETWEEN INTESTINAL FUNCTION AND EXPOSURE TO SORAFENIB IN ADULT CANCER PATIENTS (2012) (0)
- Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history (2019) (0)
- Individualized Pazopanib Dosing—Letter (2017) (0)
- Prognostic value of the nutritional status in patients with metastatic non-small cell lung cancer treated with immune checkpoints inhibitors (2020) (0)
- O052 PATIENTS' PERCEPTION OF THE EFFECTS OF CANCER ON NUTRITIONAL STATUS AND DIET (2008) (0)
- PP080-MON: Evolution of the Prevalence of Malnutrition and its Treatment in Patients with Cancer (2014) (0)
- Reply to the letter to the (2014) (0)
- Abstract 2038: Sunitinib impact on kinome profiles of peripheral blood mononuclear cells from renal cell carcinoma patients: Do molecular effects correlate with clinical data (2016) (0)
- 1023P Relationship between 18F-FDG PET colonic uptake, resting energy expenditure and immune checkpoint inhibitors efficacy in metastatic non-small cell lung cancer (NSCLC) patients: Preliminary results of the MICROBIO-TEP study (2022) (0)
- changes are marked in yellow Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in osteosarcoma patients (2017) (0)
- 2547 Low abiraterone plasma concentration fails to induce PSA regression in metastatic castration-resistant prostate cancer patients (2015) (0)
- Contents Vol. 231, 2015 (2015) (0)
- Plasma exposure is a crucial determinant for the anti-tumor activity of abiraterone in metastatic castration-resistant prostate cancer patients: Co-029 (2016) (0)
- PP066 EFFECTS OF A THREE-MONTH HOME ENTERAL NUTRITION (HEN) ON QUALITY OF LIFE (QOL): A PROSPECTIVE MULTICENTRE OBSERVATIONAL STUDY (2010) (0)
- Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer. (2014) (0)
- PP104-SUN: Discordance between Physicians and Patients in Nutritional Assessment in Elderly Patients with Cancer; Subgroup Analysis from the French Nutricancer 2012 Survey (2014) (0)
- [Phase I clinical trials in oncology: ethical issues]. (2004) (0)
- [Anti-ErbB targeted therapy and urothelial tumors]. (2005) (0)
- Identification of patients at risk for severe toxicity under PD1 inhibitors: role of sarcopenic overweight (2016) (0)
- 3451 Insulin-resistance in sarcoma patients: analysis of a prospective cohort (2015) (0)
- Abstract 4929: A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients (2018) (0)
- Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma. (2019) (0)
- PCN327 - CHALLENGES AND OPPORTUNITIES IN CLINICAL NUTRITION IN ONCOLOGY: AVAILABLE EVIDENCE, REAL WORLD PRACTICES, AND THE WAY FORWARD (2018) (0)
- 1073P Relationship between basal metabolism, nivolumab clearance and survival in metastatic non-small cell lung cancer patients of the ELY study (2022) (0)
- Prediction of short-term outcome in terminally ill cancer patients (2007) (0)
- Malnutrition in cancer patients: Is late diagnosis a missed opportunity to improve care? (2018) (0)
- [Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)]. (2008) (0)
- PP091-SUN RELATIONSHIP BETWEEN REST METABOLIC RATE AND NUTRITIONAL, INFLAMMATORY STATUS AND CANCER STAGE: A PROSPECTIVE OBSERVATIONAL STUDY IN CANCER PATIENTS (2013) (0)
- [Treatment of colorectal cancer: present advances]. (2012) (0)
- Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention. (2018) (0)
- Impact of FDG PET-CT on the decision making in patients suspected of ovarian carcinoma recurrence (2007) (0)
- Determinants for the decision of chemotherapy in advanced cancer patients. (2014) (0)
- Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria (2017) (0)
- Pemetrexed (Pem), oxaliplatin (Ox), and bevacizumab (Beva) as first-line therapy in patients (pts) with stage IV lung adenocarcinoma. (2011) (0)
- Performance diagnostique de la « Geriatric Depression Scale » pour le repérage de la dépression chez les sujets âgés atteints de cancer : l’étude de cohorte ELCAPA (2018) (0)
- Pharmacokinetic evaluation of the auto-inductive effect of a single dose of ifosfamide administered each 15 days (2005) (0)
- How should we manage bevacizumab toxicity in lung cancer patients (2014) (0)
- Insulinorésistance et cancer : étude du HOMA dans une cohorte de patients atteints de cancer (2013) (0)
- Reply to N Dominguez and T Canada. (2017) (0)
- Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study. (2019) (0)
- Relations entre fixation colique du 18FDG en TEP, dépense énergétique de repos et efficacité de l’immunothérapie chez des patients ayant un cancer pulmonaire non à petites cellules traités par immunothérapie : résultats préliminaires de l’étude MICROB (2023) (0)
- 1136P Relationship between caloric intakes and sensitivity to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients: The ELY-2 study (2022) (0)
- Identification of baseline parameters associated with the inter-individual variability in cytidine deaminase serum activity, a key enzyme in the metabolism of pyrimidine analogue (2016) (0)
- Malnutrition Is Perceived Differently By Patients, Relatives and Physicians In Routine Hematology Practice. Subgroup Analysis Of The French Cross-Sectional Nutricancer 2012 Survey (2013) (0)
- Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria. (2015) (0)
- 1528PRELATIONSHIP BETWEEN REST METABOLISM AND PERFORMANCE STATUS IN CANCER PATIENTS: A PROSPECTIVE STUDY IN 161 PATIENTS. (2014) (0)
- Determination of a score to predict life-expectancy in terminally ill cancer patients (2008) (0)
- Clinical and pharmacological parameters associated with nivolumab toxicity. (2018) (0)
- Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). (2017) (0)
- Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients. (2015) (0)
- The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort (2019) (0)
- PP061-SUN FACTORS ASSOCIATED WITH IMPROVEMENT OF QUALITY OF LIFE (QOL) IN PATIENT WITH CANCER UNDERGOING A 3-MONTH HOME ENTERAL NUTRITION (HEN) (2011) (0)
- Aggressiveness of care at the end of life in patients with localized and advanced bladder cancer. (2016) (0)
- Abstract P5-17-04: Management of Antiangiogenics' Renovascular Safety in breast cancer. Subgroup and intermediate results of the MARS Study. (2012) (0)
- 1057 Development and validation of a machine-learning-derived RNAseq prognostic signature in endometrial cancer (2021) (0)
- Joint Disorders Frequency and Structural Changes during Anastrozole Adjuvant Treatment in Early Breast Cancer: A Prospective Trial (D5392L00013). (2009) (0)
- Supplemental parenteral nutrition in cancer care: why, who, when (2022) (0)
- Changes in blood pressure and arterial mechanical properties after antiangiogenic drugs: association with cancer progression and mortality (2013) (0)
- 371 Potential benefit of pharmacokinetically-guided dosing strategy for the decision making in cancer patients treated with sunitinib (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With François Goldwasser?
François Goldwasser is affiliated with the following schools:
